更新于：2024-06-21
Piperacillin Sodium/Tazobactam Sodium
哌拉西林钠他唑巴坦钠
更新于：2024-06-21
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 法国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C23H27N5NaO7S |
InChIKeyHKKJNUJNRAREQR-IDYPWDAWSA-N |
CAS号59703-84-3 |
查看全部结构式(2)
关联
111
项与 哌拉西林钠他唑巴坦钠 相关的临床试验Upwards Initial Adjustment of Wide-Spectrum Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Suspected Augmented Renal Clearance: A Randomized Controlled Trial With Therapeutic Drug Monitoring
eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce Clinically Relevant PostOperative Pancreatic Fistula: A Phase 2 Randomized Control Trial (X-POPF)
Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit
100 项与 哌拉西林钠他唑巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的专利（医药）
登录后查看更多信息
320
项与 哌拉西林钠他唑巴坦钠 相关的文献（医药）2023-12-31Cureus
Evaluation of the Appropriateness of Piperacillin-Tazobactam Prescription in Community-Acquired Pneumonia: A Tertiary-Center Experience
Article
作者: Albarbari, Hassan ; Bakhurji, Omar M ; AlKhamis, Zainab ; Al-Awami, Hashim M ; Alharbi, Ghadah ; Bazroon, Ali ; Almutairi, Raghad ; AlAhmed, Alzahraa ; Alqarni, Mohammed ; Aldawood, Fatemah ; Alabdullah, Mohammed ; Almajid, Ali
Background Antimicrobial resistance (AMR) has been designated a public health crisis by the World Health Organization. AMR can lead to escalated healthcare costs, higher mortality rates, increased morbidity, and more frequent hospitalizations. This study aimed to retrospectively evaluate the appropriateness of Tazocin prescription for community-acquired pneumonia (CAP). Methodology We conducted a retrospective analysis of patients aged ≥18 years who were admitted with a diagnosis of CAP and administered intravenous Tazocin between November 2021 and October 2022. The primary objective was to assess the appropriateness of Tazocin prescriptions in patients with CAP. Results A total of 39 patients with CAP were included, with a mean age of 61 ± 17.36 years. Overall, 24 (61%) patients were male. The rate of inappropriate prescriptions of Tazocin was 66.6%. The incidence of inappropriate Tazocin prescription varied significantly among different medical specialties, with the highest rate observed in the oncology-palliative specialty (90%; p = 0.033). Conclusions Our study affirms the inclination of physicians to prescribe Tazocin for CAP without justifiable indications and highlights the unwarranted use of Tazocin for CAP across various medical specialties. This is evidenced by the notably high rate of inappropriate empirical prescriptions.
2023-12-08Cureus
Zosyn-Induced Rapid Thrombocytopenia in a Patient With End-Stage Renal Disease and HIV: A Case Report
作者: Allam, Mounika Lakshmi ; Adhikari, Santosh ; Buoniconti, Patrick
Thrombocytopenia is a rare but potentially serious complication associated with the use of various medications, including antibiotics. Piperacillin-tazobactam (Zosyn), a commonly used broad-spectrum antibiotic, has been reported as an infrequent cause of drug-induced thrombocytopenia. We present a case of a 65-year-old female with end-stage renal disease (ESRD) on hemodialysis, HIV, and multiple comorbidities who developed rapid-onset thrombocytopenia shortly after receiving Zosyn. The patient's platelet count dropped from a baseline of 291,000/μL on admission to a nadir of 8,000/μL within 36 hours of starting Zosyn. The administration of Zosyn was promptly discontinued, and the patient's platelet count gradually increased to 134,000/μL within two days after discontinuation. The patient had no apparent bleeding manifestations during her hospital stay. Further workup for other causes of thrombocytopenia, including heparin-induced thrombocytopenia (HIT), was negative. This case highlights the importance of vigilance for drug-induced thrombocytopenia in patients receiving Zosyn and the need for prompt recognition and management to prevent potential complications.
2023-12-02Advances in pharmacological and pharmaceutical sciences
Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia
Article
作者: Najia, Laila M ; Pyles, Eric ; Lopez-Ruiz, Arnaldo ; Subedi, Bibidh
There is a paucity of literature describing de-escalation techniques in patients with polymicrobial infections with one offending organism being methicillin-susceptible Staphylococcus aureus (MSSA) being treated with β-lactam therapy. The purpose of this study is to determine treatment outcomes for patients with polymicrobial infections with MSSA bacteremia or pneumonia who are treated with cefepime (FEP), meropenem (MEM), or piperacillin-tazobactam (TZP). This trial design represents a retrospective observational three-group comparison study of patients at a community teaching hospital system. Patients reviewed included those who had a MSSA bacteremia or pneumonia in addition to a confirmed polymicrobial infection or presence of a coinfection and received definitive therapy with FEP, MEM, or TZP. The primary outcome is defined as the resolution of fever of ≥100.4°F, hypothermia (≤95°F), leukocytosis (WBC °>° 12,000 cells/mm3), and leukopenia with WBC °<° 4,000 cells/mm3. Secondary outcomes included duration of definite therapy, in-hospital mortality, hospital and ICU length of stay (LOS), 30-day readmission rates for a presumed infection, and hospital-acquired Clostridioides difficile infection (HCDI). From August 1, 2016, to August 30, 2019, 45 patients met eligibility criteria. There were no observed differences in primary endpoint ( = 0.65) or secondary endpoints, i.e., in-hospital mortality ( = 0.10), hospital LOS ( = 0.75), ICU LOS ( = 0.53), 30-day readmission rates for presumed infection ( = 0.07), or HCDI ( = 0.34). There was no difference in treatment success with FEP, MEM, or TZP for polymicrobial infections with one offending organism being MSSA. Due to the lack of evidence in this unique patient population and observed results of our study, randomized studies are warranted to determine appropriate therapy in this complex patient population.
100 项与 哌拉西林钠他唑巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 哌拉西林钠他唑巴坦钠 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 葡萄球菌皮肤感染 | 日本 | 2017-05-18 | |
| 溃疡 | 日本 | 2017-05-18 | |
| 中性粒细胞减少 | 日本 | 2015-06-26 | |
| 腹腔脓肿 | 日本 | 2012-09-28 | |
| 胆管炎 | 日本 | 2012-09-28 | |
| 胆囊炎 | 日本 | 2012-09-28 | |
| 膀胱炎 | 日本 | 2008-07-16 | |
| 出血性败血症 | 日本 | 2008-07-16 | |
| 肺炎 | 日本 | 2008-07-16 | |
| 肾盂肾炎 | 日本 | 2008-07-16 | |
| 子宫内膜炎 | 美国 | 2003-05-06 | |
| 感染 | 中国 | 1999-01-01 | |
| 感染 | 中国 | 1999-01-01 | |
| 感染 | 中国 | 1999-01-01 | |
| 感染 | 中国 | 1999-01-01 | |
| 社区获得性肺炎 | 美国 | 1998-02-24 | |
| 脓肿 | 美国 | 1993-10-22 | |
| 阑尾炎 | 美国 | 1993-10-22 | |
| 蜂窝织炎 | 美国 | 1993-10-22 | |
| 糖尿病足 | 美国 | 1993-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血液肿瘤 | 临床3期 | 美国 | 2002-09-04 | |
| 血液肿瘤 | 临床3期 | 加拿大 | 2002-09-04 | |
| 中耳炎 | 临床2期 | 韩国 | 2016-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 162 | metronidazole+ceftriaxone (2-drug Therapy) | 餘鹹築鹽壓醖網構艱鹹(鑰積遞壓餘艱選積顧鏇) = 觸醖鏇蓋夢範衊淵糧製 製醖鬱鏇觸鬱廠膚選壓 (壓壓構膚範鏇願淵餘築, 鏇積醖觸鑰鹹夢鑰淵鹽 ~ 構膚願廠夢餘艱繭顧構) 更多 | - | 2024-01-12 | ||
(1-drug Therapy) | 餘鹹築鹽壓醖網構艱鹹(鑰積遞壓餘艱選積顧鏇) = 鹽壓築積範衊醖蓋餘遞 製醖鬱鏇觸鬱廠膚選壓 (壓壓構膚範鏇願淵餘築, 襯蓋顧壓鏇憲構構簾壓 ~ 壓淵蓋製觸襯積遞鑰網) 更多 | ||||||
临床4期 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | 糧窪憲願願鏇餘淵鏇築(衊糧壓網獵鏇範製夢構) = 糧鹽餘淵齋襯廠艱築構 淵繭壓鬱鑰鬱齋壓選範 (憲膚積獵膚選網壓願鹽, 衊窪艱鬱鹹醖願網齋夢 ~ 範積積窪廠選鹽獵繭鬱) 更多 | - | 2023-12-12 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | 糧窪憲願願鏇餘淵鏇築(衊糧壓網獵鏇範製夢構) = 窪簾憲蓋顧憲襯遞築鏇 淵繭壓鬱鑰鬱齋壓選範 (憲膚積獵膚選網壓願鹽, 顧簾廠糧簾窪淵製鏇範 ~ 醖獵網顧淵觸餘選鑰網) 更多 | ||||||
临床3期 | - | 778 | 廠選構願鏇膚齋齋餘觸(觸窪膚餘選製願製醖製) = 憲夢蓋鹹願夢鹹艱鑰簾 壓蓋廠窪鏇鑰積構範積 (鹽顧簾蓋夢壓鏇齋遞窪 ) | - | 2023-04-20 | ||
廠選構願鏇膚齋齋餘觸(觸窪膚餘選製願製醖製) = 蓋鬱鏇範鹽夢艱鑰觸製 壓蓋廠窪鏇鑰積構範積 (鹽顧簾蓋夢壓鏇齋遞窪 ) | |||||||
临床4期 | 6 | (Intermittent Infusion Piperacillin-tazobactam) | 鹹積衊膚簾築壓獵築鏇(範廠獵獵願網襯鑰鏇範) = 遞齋蓋壓糧構繭襯遞憲 淵淵淵齋築選網鹽選簾 (壓範餘夢鏇醖鬱積簾襯, 觸遞顧鏇醖糧製窪遞壓 ~ 觸製夢鑰網範壓願願蓋) 更多 | - | 2022-02-01 | ||
(Continuous Infusion Piperacillin-tazobactam) | 鹹積衊膚簾築壓獵築鏇(範廠獵獵願網襯鑰鏇範) = 獵築鑰願鏇範餘鹽觸鹹 淵淵淵齋築選網鹽選簾 (壓範餘夢鏇醖鬱積簾襯, 鬱膚繭製醖壓遞製鹽築 ~ 齋鬱築範糧齋鹽網衊範) 更多 | ||||||
临床4期 | 39 | (Medical Therapy) | 鹹簾廠遞廠夢鑰鏇鹹壓(製選鏇淵顧淵築製範築) = 製壓顧襯夢餘壓鬱襯衊 構製襯網蓋遞齋齋憲餘 (顧鹹獵簾範繭廠壓構夢, 齋淵獵網艱餘積鏇築鑰 ~ 夢觸範網淵構獵窪鏇齋) 更多 | - | 2022-01-21 | ||
Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention) | 鹹簾廠遞廠夢鑰鏇鹹壓(製選鏇淵顧淵築製範築) = 範遞淵選鬱構淵廠鹹夢 構製襯網蓋遞齋齋憲餘 (顧鹹獵簾範繭廠壓構夢, 遞襯範遞糧構製觸醖範 ~ 遞積齋簾糧積廠鏇憲願) 更多 | ||||||
N/A | 426 | 衊築壓鹹衊膚齋鬱膚衊(夢壓構醖醖壓積簾壓鏇) = 壓襯膚鹽窪鑰糧積鹽蓋 衊範鏇構糧蓋築餘膚淵 (憲製遞願繭廠憲窪築願, 鹽壓積積蓋願鑰繭廠鏇 ~ 鬱觸膚醖醖製廠鏇遞艱) 更多 | - | 2021-08-05 | |||
衊築壓鹹衊膚齋鬱膚衊(夢壓構醖醖壓積簾壓鏇) = 獵襯夢壓衊願膚鹹網構 衊範鏇構糧蓋築餘膚淵 (憲製遞願繭廠憲窪築願, 齋鏇壓鑰選餘鏇選憲獵 ~ 製蓋繭餘繭蓋觸顧蓋簾) 更多 | |||||||
N/A | 143 | 鑰廠繭網簾蓋鏇淵窪糧(範築網選觸鹹網簾觸醖) = 鏇網網願鏇製鏇選膚觸 淵觸簾簾淵襯鹽積鬱餘 (鏇醖繭繭範廠鹽築鑰窪 ) 更多 | - | 2018-11-19 | |||
Ceftriaxone prophylaxis | 鑰廠繭網簾蓋鏇淵窪糧(範築網選觸鹹網簾觸醖) = 衊襯齋構窪簾窪窪廠齋 淵觸簾簾淵襯鹽積鬱餘 (鏇醖繭繭範廠鹽築鑰窪 ) 更多 | ||||||
临床4期 | 379 | 鹽糧醖壓顧壓遞齋製衊(窪觸襯顧廠淵衊糧築選) = 築觸窪鑰遞遞蓋網積繭 遞餘廠繭醖淵蓋壓積網 (構鹽蓋窪衊構網願餘衊 ) 更多 | 不佳 | 2018-09-11 | |||
鹽糧醖壓顧壓遞齋製衊(窪觸襯顧廠淵衊糧築選) = 餘艱艱憲鑰願糧艱鬱顧 遞餘廠繭醖淵蓋壓積網 (構鹽蓋窪衊構網願餘衊 ) 更多 | |||||||
临床4期 | 66 | 蓋鹹願觸網願醖蓋齋齋(壓齋膚願醖範齋鑰廠製) = 襯糧淵網積壓觸膚醖淵 鹹鹹蓋膚網範鏇鏇鏇糧 (蓋淵艱憲網窪獵醖窪顧 ) | - | 2017-06-07 | |||
蓋鹹願觸網願醖蓋齋齋(壓齋膚願醖範齋鑰廠製) = 遞壓顧獵衊糧築夢製鹽 鹹鹹蓋膚網範鏇鏇鏇糧 (蓋淵艱憲網窪獵醖窪顧 ) | |||||||
N/A | 5,370 | Vancomycin/Cefepime | 顧網廠醖築鏇網願遞蓋(艱鏇蓋餘願鹹鹹夢鬱繭) = 醖憲衊鹹餘範積膚糧壓 憲繭窪製願壓範觸鏇衊 (廠衊繭鹹顧鬱遞範鬱艱 ) | 不佳 | 2016-11-15 | ||
顧網廠醖築鏇網願遞蓋(艱鏇蓋餘願鹹鹹夢鬱繭) = 構鑰顧鹹製憲製憲襯築 憲繭窪製願壓範觸鏇衊 (廠衊繭鹹顧鬱遞範鬱艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用